ropinirole Side Effects
Also known as: Requip
Analysis of 14,664 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
14,664
Death-Related
1,369
9.3% of reports
Hospitalizations
4,485
30.6% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 1,369 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 622 |
| COMPLETED SUICIDE | 139 |
| FALL | 76 |
| PNEUMONIA | 74 |
| CARDIAC ARREST | 63 |
| PARKINSON^S DISEASE | 63 |
| HALLUCINATION | 56 |
| ACUTE KIDNEY INJURY | 53 |
| TOXICITY TO VARIOUS AGENTS | 52 |
| RENAL FAILURE | 49 |
| DYSPNOEA | 46 |
| CHRONIC KIDNEY DISEASE | 39 |
| OFF LABEL USE | 38 |
| ASTHENIA | 37 |
| CARDIAC FAILURE CONGESTIVE | 33 |
| RESPIRATORY FAILURE | 33 |
| MYOCARDIAL INFARCTION | 32 |
| NAUSEA | 32 |
| SEPSIS | 31 |
| DIARRHOEA | 30 |
Reactions in Hospitalization Reports
Top reactions in 4,485 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| FALL | 551 |
| DYSPNOEA | 328 |
| PNEUMONIA | 314 |
| FATIGUE | 285 |
| NAUSEA | 253 |
| URINARY TRACT INFECTION | 235 |
| HALLUCINATION | 224 |
| ASTHENIA | 223 |
| PAIN | 213 |
| DRUG INEFFECTIVE | 205 |
| CONFUSIONAL STATE | 196 |
| WEIGHT DECREASED | 195 |
| DIZZINESS | 194 |
| DIARRHOEA | 185 |
| DYSKINESIA | 179 |
| GAIT DISTURBANCE | 178 |
| MALAISE | 175 |
| VOMITING | 173 |
| ACUTE KIDNEY INJURY | 160 |
| HYPOTENSION | 152 |
Nearby — Related Medications
What the FAERS Data Reveals About ropinirole Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 14,664 voluntary reports linked to ropinirole and its brand equivalents (Requip), spanning 2004 through 2025. Of those, 1,369 (9.3%) listed death as an outcome and 4,485 (30.6%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 62% were female and 38% male; age distribution skews toward 45-64, with 3,446 reports in that bracket. The single most reported reaction is drug ineffective with 1,153 submissions, followed by fall and fatigue.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.